Objective: Newborn screening laboratories vary in the values that are used to define congenital hypothyroidism. Defining congenital hypothyroidism is particularly complex in premature neonates because prematurely born infants often have a low free thyroxine value and low or normal TSH value, termed as transient hypothyroxinemia of prematurity. In a multicenter (n ¼ 11 sites) trial, we randomly allocated premature neonates with a gestational age of 23 to 29 and 6/7 weeks to one of two parenteral nutrition approaches. The primary objective of our trial was to measure the effect of two distinct strategies of parenteral nutrition on neonatal growth and blood amino acids. A protocol defined secondary aim of our clinical trial was the evaluation of the influence of gestational age, time and the degree of amino-acid supplementation on total thyroxine levels. We hypothesized that an increase of amino-acid supplementation would be associated with the normalization of serum amino acids and that this would improve thyroxine synthesis.
Introduction
Newborn screening laboratories vary in the values they use to define congenital hypothyroidism. 1, 2 Defining congenital hypothyroidism is particularly complex in premature neonates because prematurely born infants often have a low free thyroxine value and a low or normal TSH value, termed as transient hypothyroxinemia of prematurity. Premature deliveries account for approximately 12 .5% of all births in the United States and The National Center for Health Statistics estimates that over 500 000 babies are born prematurely each year. 3 Congenital hypothyroidism is estimated to occur in 1 in 4000 newborns and hypothyroidism that goes undetected results in poor growth and developmental delay. 2 Thyroxine levels are lower in sick preterm neonates than those in well preterm neonates. [4] [5] [6] Normal thyroid hormone levels promote normal growth and development in the fetus and prematurely born neonates. [7] [8] [9] [10] [11] The data provided in this article are taken from a randomized, double-blind clinical trial, which examined whether increased intravenous amino-acid supplementation would improve growth. In this trial, it was hypothesized that increased amino-acid supplementation would improve growth and well being and that normalization of serum amino acids would increase thyroxine levels. The primary study did not demonstrate improved growth or reduced morbidity. 12 However, it was noted that changes in thyroxine levels did occur during the course of the trial. 12 A secondary objective was the evaluation of the influence of gestational age, time and the degree of amino-acid supplementation on thyroxine levels.
Methods

Study objectives
The primary objective of our multicenter (n ¼ 11) clinical trial was to measure the effect of two distinct strategies of parenteral nutrition on neonatal growth and blood amino acids. 12 A secondary aim of our clinical trial was the evaluation of the influence of gestational age, time and the degree of amino-acid supplementation on thyroxine levels. We hypothesized that an increase of amino-acid supplementation would be associated with the normalization of serum amino acids and that this would improve thyroxine synthesis.
Patient selection
Neonates that had an estimated gestational age between 23 and 0/7 weeks and 29 and 6/7 weeks were less than 48 h of age at randomization, were inborn, obtained parental consent and were eligible to participate in the study. Institutional Review Boards at each hospital (n ¼ 11) approved the protocol. Patients were excluded if they had a major chromosomal or congenital anomaly.
Treatment groups
Neonates were randomized to one of two treatment groups. These two treatment groups represented the extremes of clinical practice that the study investigators were willing to evaluate. In one group the maximum dose was 2.5 g kg À1 per day group (2.5 group). Amino-acid supplementation was started at 1.0 g kg À1 per day and advanced by 0.5 g kg À1 per day to a maximum of 2.5 g kg À1 per day on day 4 of treatment. Amino-acid supplementation decreased to 1.0 g kg À1 per day once feedings reached 80 to 100 ml kg À1 per day. In the second group, the maximum dose was 3.5 g kg À1 per day group (3.5 group). Amino-acid supplementation started at 1.5 g kg À1 per day of amino acids and advanced by 1 g kg À1 per day to a maximum of 3.5 g kg À1 per day by day 3 of treatment. Amino-acid supplementation decreased to 2.0 g kg À1 per day once feedings reached 80 to 100 ml kg À1 per day. In both treatment groups, the amino-acid supplementation was stopped once feedings reached 100 to 130 ml kg À1 per day and the patient was considered to have completed treatment. Subsequent parenteral nutrition was given at the discretion of the health-care team.
Measurement of thyroxine levels
Filter paper blood spots were obtained on the day of randomization, and on days 7 and 28 of life to monitor laboratory values. Total thyroxine levels were analyzed from dried blood spots using tandem mass spectrometry following methanol extraction using essentially the same method as tandem mass spectrometry analysis of amino acids. 13 Product ion spectra show a transition of 833.8 to 731.8 (102 Da). A selected reaction monitoring for thyroxine and 13C6-thyroxine was added to the tandem mass spectrometry analysis of acylcarnitines and amino acids. Analysis of thyroxine by tandem mass spectrometry compares well with immunoassay. The mean of 10 225 newborn screening specimens was 14.4 mg per 100 ml (range, 2.4 to 33) for tandem mass spectrometry and 14.1 mg per 100 ml (range, 1.4 to 71.8) for AutoDELFIA. The tandem mass spectrometry assay was linear with a correlation coefficient of 0.998. We determined a tandem mass spectrometry detection limit of 0.97 mg per 100 ml.
To provide 'normal' reference values (reference in Figure 1 ), we calculated the median and the 10th and 90th percentile for tyrosine and thyroxine using 1000 normal term newborn values (sample obtained in the first 7 days after birth).
Statistical evaluation
The median and quartiles were calculated when the data were not normally distributed. Differences between treatment groups were compared using univariate and multivariate techniques. Figure 1 Changes in thyroxine (a) and tyrosine (b) levels over time and with in gestational age groups. *On day 7, neonates with a gestational age of 28 or 29 weeks had significantly higher thyroxine and tyrosine levels than those of the most immature neonates (23 to 25 and 26 to 27 groups, P<0.05). On day 28, the most immature neonates still had significantly lower thyroxine levels than those of the most mature neonates. To provide 'normal' reference values, we calculated the median and the 10th and 90th percentile for tyrosine and thyroxine using 1000 normal term newborn values (sample obtained in the first 7 days after birth).
protein dose) were evaluated with two-tailed Student's t-tests and nonparametric continuous data were assessed with a Kruskal-Wallis analysis of variance (amino-acid levels, thyroxine levels, Apgar's scores and degree of amino-acid supplementation). Categorical variables (for example, race and gender) were evaluated with a two-tailed w 2 -test and Fisher's exact test. All statistical analysis was done using JMP Release 5.0.1a (SAS Institute Inc., Cary, NC, USA).
Results
Enrollment included 122 neonates from 11 sites, 64 in the 3.5 group and 58 in the 2.5 group. Of the 122 patients enrolled, 11 patients did not complete the study. Three patients died before 28 days. Five patients were withdrawn from the study, three in the 3.5 group and two in the 2.5 group. One patient was felt to be too sick to continue by the attending neonatologist in the study and two patients were transferred out of the study facility before 28 days and follow-up laboratory was not available. Removing the 11 patients who failed to complete the study protocol does not change our results; so we have reported only the intent to treat analysis. An 'intent-to-treat' approach was used and the tables and figures reflect 'all enrolled' neonates categorized by treatment group.
There were no significant differences in demographics or baseline characteristics for the two treatment groups and the higher dose of amino-acid supplementation did not improve any measure of growth (Table 1) . Tyrosine levels decreased from days 1 to 7. On day 7, tyrosine levels were low in 47.5% of the neonates. 12 Increased supplementation did not influence thyroxine levels or how they changed over time (Table 1 and Figure 1 ).
Both gestational age and time did influence thyroxine levels ( Table 1 and Figure 1 ). For the overall sample of preterm neonates Abbreviations: EGA, estimated gestational age; max, maximum.
Thyroxine levels in premature neonates AS Kelleher et al enrolled in the trial, thyroxine levels on day 7 were lower than those on days 1 and 28 (Table 1 ; day 1, 7.7 mg per 100 ml; day 7, 6.1 mg per 100 ml and day 28, 8.2 mg per 100 ml). The most dramatic changes in thyroxine levels occurred in the most preterm neonates (23 to 25 weeks gestational age, see Figure 1 ). On day 7, thyroxine levels were lowest in the most immature group of preterm neonates and higher in the most mature neonates. On day 7, the median thyroxine level in neonates with an estimated gestational age between 23 and 25 was 3.2 mg per 100 ml, with an interquartile range of 2.6 to 4.8 mg per 100 ml. In contrast (on day 7), neonates with an estimated gestational age between 28 and 29 had a median value of 6.7 mg per 100 ml with an interquartile range of 5.9 to 9.5 mg per 100 ml. By day 28, thyroxine levels had increased but the most preterm neonate had values that were still significantly lower than those of the most mature neonates ( Figure 1a) .
Discussion
This study demonstrated that both time and gestational age influence thyroxine values. The degree of amino-acid supplementation did not influence thyroxine levels. The most preterm neonates (23 to 25 weeks estimated gestational age (EGA)) had the lowest levels and the most dramatic changes in thyroxine over time.
It was hypothesized that an increase of amino-acid supplementation would be associated with the normalization of serum amino acids. In the primary study, several amino-acid levels were found to be consistently low. For this inquiry, the serum tyrosine levels were of particular interest. Tyrosine is an important precursor for the formation of thyroglobulin, a protein which is essential for the synthesis of thyroxine.
14 Tyrosine levels decreased from days 1 to day 7. On day 7, tyrosine levels were low in 47.5% of the neonates. 12 While these data are not definitive, the changes in thyroxine levels and tyrosine levels look similar (Figure 1) . The low thyroxine levels may, in part, be due to tyrosine deficiency. However, other unmeasured factors such as maturation of the endocrine system, changes in thyroid metabolism and exposure to drugs that influence thyroid metabolism may have confounded our results. Further studies regarding our observations may be valuable.
The American Academy of Pediatrics currently recommends obtaining thyroxine levels in the premature neonate within 7 days of birth. 15 The results from the present study showed thyroxine values were lower on day 7 as compared to baseline values. On day 28, values were similar to baseline values (Figure 1) . These results were consistent with previous reports that demonstrated the influence of both time and gestational age on thyroxine levels. 5 Defining appropriate screening methods for identifying premature neonates with congenital hypothyroidism are complex, and the change in total thyroxine levels with time and the difference in thyroxine levels between gestational age groups make defining normal even more complex. We did not measure free thyroxine or thyroid stimulating hormone values and this limits our ability to assess thyroid function.
In summary, increased amino-acid supplementation did not alter total thyroxine levels. Time and gestational age-specific values for assessment of thyroid function are needed to define true hypothyroidism and to identify patients who might benefit from treatment. Until national standards are defined, research on treatment is impossible.
